Haiquan Fang
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Receptor Mechanisms and Signaling, Nicotinic Acetylcholine Receptors Study, Pharmacological Receptor Mechanisms and Effects, HIV Research and Treatment
Most-Cited Works
- → Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions(2003)206 cited
- → Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns(2009)62 cited
- → Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents(2012)51 cited
- → Inhibitors of HIV-1 attachment. Part 8: The effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors(2012)40 cited
- → A survey of core replacements in indole-based HIV-1 attachment inhibitors(2019)24 cited
- → Development of 1H-Pyrazolo[3,4-b]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators(2016)22 cited
- → Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship(2016)18 cited
- → BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia(2017)14 cited
- → Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists(2016)12 cited
- → Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties(2022)10 cited